WO2010035292A8 - The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections - Google Patents

The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections Download PDF

Info

Publication number
WO2010035292A8
WO2010035292A8 PCT/IT2008/000609 IT2008000609W WO2010035292A8 WO 2010035292 A8 WO2010035292 A8 WO 2010035292A8 IT 2008000609 W IT2008000609 W IT 2008000609W WO 2010035292 A8 WO2010035292 A8 WO 2010035292A8
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
prevention
medicament
human monoclonal
therapeutic treatment
Prior art date
Application number
PCT/IT2008/000609
Other languages
French (fr)
Other versions
WO2010035292A1 (en
Inventor
Roberto Burioni
Massimo Clementi
Original Assignee
Natimab Therapeutics S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natimab Therapeutics S.R.L. filed Critical Natimab Therapeutics S.R.L.
Priority to PCT/IT2008/000609 priority Critical patent/WO2010035292A1/en
Publication of WO2010035292A1 publication Critical patent/WO2010035292A1/en
Publication of WO2010035292A8 publication Critical patent/WO2010035292A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to human monoclonal antibodies capable of recognizing the conformational epitope of the HCV E2 glycoprotein recognized by the e8 Fab and cross-reacting with a plurality of different HCV genotypes, as a medicament for the treatment or prevention of HCV infections. A pharmaceutical composition for the treatment or prevention of HCV infections, comprising an antibody as defined above, preferably the e8 Fab, as well as pharmaceutically acceptable excipients, vehicles or diluents, is also disclosed.
PCT/IT2008/000609 2008-09-24 2008-09-24 The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections WO2010035292A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IT2008/000609 WO2010035292A1 (en) 2008-09-24 2008-09-24 The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2008/000609 WO2010035292A1 (en) 2008-09-24 2008-09-24 The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections

Publications (2)

Publication Number Publication Date
WO2010035292A1 WO2010035292A1 (en) 2010-04-01
WO2010035292A8 true WO2010035292A8 (en) 2010-07-01

Family

ID=40266015

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2008/000609 WO2010035292A1 (en) 2008-09-24 2008-09-24 The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections

Country Status (1)

Country Link
WO (1) WO2010035292A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012107589A1 (en) * 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
RU2539770C1 (en) 2013-12-27 2015-01-27 Татьяна Николаевна Власик Method of neutralisation of hepatitis c virus, completely human homogeneous antibody against hepatitis c virus (versions), composition of completely human homogeneous antibodies against hepatitis c virus and hybrid mouse/human cell line - producent of completely human homogeneous antibodies against hepatitis c virus (versions)
EP3121273A4 (en) * 2014-03-20 2017-08-30 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Antibody having infection-inhibiting activity against hepatitis c virus
WO2016036252A2 (en) * 2014-09-05 2016-03-10 Aimm Therapeutics B.V. Hepatitis c virus specific antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053332A2 (en) * 2001-08-20 2003-07-03 Myriad Genetics, Inc Composition and method for treating viral infection
ITRM20020049A1 (en) * 2002-01-30 2003-07-30 Biostrands S R L FAB FRAGMENTS OF HUMAN MONOCLONAL ANTIBODIES DIRECTED AGAINST HCV GLYCROTEIN E2 AND EQUIPPED WITH NEUTRALIZING IN VITRO POWER.
RS53258B (en) * 2007-02-21 2014-08-29 University Of Massachusetts Human antibodies against hepatitis c virus (hcv) uses thereof

Also Published As

Publication number Publication date
WO2010035292A1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
HRP20160151T1 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
HRP20171992T1 (en) Cgrp antibodies
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
WO2007115049A3 (en) Humanized monoclonal antibodies to hepatocyte growth factor
JP2012518624A5 (en)
WO2006041866A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
EA201000018A1 (en) LYOPHILIZED MEDICINAL FORMS OF IMMUNOHLOBULINS AND METHODS FOR THEIR RECOVERY
CR8698A (en) MONOCLONAL ANTIBODIES TO THE HEPATOCITE GROWTH FACTOR
JP2008538564A5 (en)
NZ615012A (en) Combinatorial therapy involving alpha5beta1 antagonists
WO2012006596A3 (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
WO2007130491A3 (en) Patient customized therapeutic regimens
WO2008071418A3 (en) Use of the endoglycosidase endos for treating immunoglobulin g mediated diseases
JP2015522252A5 (en)
RU2010127291A (en) THERAPEUTIC AGAINST ITCH
WO2007106617A3 (en) Method of treatment and prophylaxis of diseases related to amyloid deposition using igm
JP2016503413A5 (en)
EA201270144A1 (en) COMBINED THERAPY FOR TREATMENT OF DIABETES
WO2012010973A3 (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
RU2015102069A (en) ANTIBODIES TO BIOTIN AND WAYS OF THEIR APPLICATION
WO2012006500A3 (en) Monoclonal antibodies against hepatitis c virus core protein
WO2010086828A3 (en) Agonist anti-trkb monoclonal antibodies
WO2010035292A8 (en) The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
WO2008017826A3 (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08877052

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 08877052

Country of ref document: EP

Kind code of ref document: A1